Search

Meeting Program

Sickle Cell Disease: From Research to Clinical Management
Please note: all times are in Central European Summer Time (CEST)

Read more

Collaboration with the EMA on Joint Clinical Assessments and Joint Scientific Consultations under the HTA Regulation

The European Hematology Association (EHA) welcomes the draft Implementing Act laying down procedural rules for the exchange of information between the Health Technology Assessment (HTA) Coordination Group, the European Commission, and the European Medicines Agency (EMA).

Read more

Young EHA

Welcome to Young EHA!As a junior member of EHA, you are part of the Young EHA family.

Read more

EHA Bilateral Collaborative Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

Read more

Specialized Working Groups

EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.

Read more

European Board for Accreditation in Hematology

Current committee members
Peter van den Burg, The Netherlands (Chair and ISBT representative—transfusion medicine)
Michelle Kenyon, United Kingdom (EBMT Nurses Group representative—Specialized Hematology Professional)
Fionnuala Ní Áinle, Ireland (ISTH representative—thrombosis and hemostasis)
Annalisa Ruggeri, Italy (Representative, clinical hematology)
Isabel Sanchez-Ortega, Spain (EBMT representative)
Ana Filipa Marques…

Read more

Travel Grants

Travel grant application is now closed 

Travel grants are intended to support young investigators in the region; therefore, applicants should be 40 years of age or young, and are reserved for applicants from Armenia, Georgia, Iran, Azerbaijan, and Türkiye.

Read more

The ‘i4MDS’ consortium looks to the future at its second general meeting

Feb 29 2024 Posted in Meeting reports Tagged i4MDS

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.

Read more

‘i4MDS’ consortium wins prestigious EHA Innovation Grant

In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.

Read more